NASDAQ:CELC Celcuity Q3 2025 Earnings Report $51.96 -0.57 (-1.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$48.66 -3.30 (-6.34%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Celcuity EPS ResultsActual EPSN/AConsensus EPS -$1.05Beat/MissN/AOne Year Ago EPSN/ACelcuity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACelcuity Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Celcuity Earnings HeadlinesCelcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ...October 18 at 6:28 AM | markets.businessinsider.comCelcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical TrialOctober 18 at 4:30 AM | globenewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.October 19 at 2:00 AM | Traders Agency (Ad)Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)October 18 at 4:30 AM | globenewswire.comDetailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast CancerOctober 18 at 4:30 AM | globenewswire.comCelcuity: Blink And You Missed ItOctober 8, 2025 | seekingalpha.comSee More Celcuity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celcuity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celcuity and other key companies, straight to your email. Email Address About CelcuityCelcuity (NASDAQ:CELC) is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors. Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval. Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions.View Celcuity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Nasdaq (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025)Citigroup (10/21/2025)3M (10/21/2025)RTX (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
